Drug Profile


Alternative Names: SKF 106615

Latest Information Update: 15 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AnorMED; University of Texas M. D. Anderson Cancer Center
  • Developer Callisto Pharmaceuticals
  • Class Anti-inflammatories; Antirheumatics; Small molecules; Spiro compounds
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Immunomodulators; Interleukin 1 modulators; Interleukin-6 modulators; Macrophage modulators; Osteoclast modulators; Proto oncogene protein c-akt inhibitors; STAT3 transcription factor inhibitors; Tumour necrosis factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Carcinoid tumour
  • New Molecular Entity No
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • Discontinued Carcinoid tumour; Inflammation; Multiple myeloma; Osteoporosis; Rheumatoid arthritis; Solid tumours

Most Recent Events

  • 28 Jan 2009 Preclinical trials in Rheumatoid arthritis in USA (PO)
  • 03 Jun 2008 Efficacy and safety data from a phase II trial in Carcinoid tumour presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
  • 16 May 2008 Interim efficacy data from a Phase-II trial in Carcinoid tumour released by Callisto Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top